Latest Olaparib Stories
Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation.
Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment.
A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study.
WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Women with breast cancer before age 55 who carry an inherited mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite, or contralateral, to their initial tumor as compared to breast cancer patients without these genetic defects.
WALTHAM, Mass., Feb.
Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.
Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors.
New findings may help explain why women who carry a mutated BRCA1 gene have greater rates of infertility as well as a greater risk for breast and ovarian cancer.
WALTHAM, Mass., Nov.
- An armed gangster.